Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival
- 1 January 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (1), 286-291
- https://doi.org/10.1158/0008-5472.can-03-1242
Abstract
Urokinase plasminogen activator (uPA) expression in breast cancer is associated with relapse and a reduction in disease-specific survival. Thus, efforts are under way to identify uPA inhibitors. By screening a chemical library of >1000 compounds, 17-allyaminogeldanamycin (17AAG) was identified as a potent inhibitor of uPA by the National Cancer Institute and is now in Phase I clinical trials. At this time, it remains unclear how 17AAG blocks uPA; one possibility is through disruption of the insulin-like growth factor I receptor (IGF-IR) pathway. This would be consistent with studies from our laboratory showing that activation of IGF-IR results in the induction of uPA protein. In the study described herein, we observed that IGF-IR and uPA were highly expressed in 87 and 55% of breast cancer by screening tumor tissue microarrays representing 930 cases. A significant proportion (52.1% = 354 of 680 cases, P < 0.0001) of the patients had tumors expressing both proteins. uPA alone (P = 0.033) or in combination with IGF-IR (P = 0.0104) was indicative of decreased disease-specific survival. Next, we demonstrated that treating MDA-MB-231 cells with increasing concentrations of 17AAG resulted in IGF-IR degradation (IC50 = 1.0 μm) and blocked signal transduction through the Akt and mitogen-activated protein kinase pathways. Finally, we found that 17AAG had a robust inhibitory effect on the production of uPA mRNAand protein in the presence of IGF-I. Thus, our study raises the possibility that 17AAG could prove to be an effective therapeutic agent for a large number of breast cancer patients by inhibiting the IGF-IR and ultimately uPA.Keywords
This publication has 21 references indexed in Scilit:
- Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast CancerLaboratory Investigation, 2003
- Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic ImmunohistochemistryLaboratory Investigation, 2002
- Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Oncogene, 2002
- Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 2002
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumoursExpert Opinion on Biological Therapy, 2001
- A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivoThe FASEB Journal, 2000
- Herbimycin A Induces the 20 S Proteasome- and Ubiquitin-dependent Degradation of Receptor Tyrosine KinasesPublished by Elsevier BV ,1995
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987